Neurescue welcomes Mette-Marie Harild to its Board of Directors

– DENMARK, Copenhagen –  Neurescue, a clinical-stage medical device company bringing to market the world’s first computer-aided balloon catheter for aortic occlusion, today announced the appointment of medical device industry veteran Mette-Marie Harild to its board of directors.

“I am very grateful and excited to welcome Mette-Marie Harild into Neurescue’s board of directors as a highly experienced and esteemed medical device executive,” said CEO, Habib Frost.

He added: “In the upcoming months, we anticipate investigational device exemption approval for the cardiac arrest application of our NEURESCUE device and 510(k) clearance for the hemorrhage application. We look forward to applying Ms. Harild’s expertise into our commercialization strategy to help bring a potentially transformative treatment option into the hands of physicians to help save patients’ hearts and minds.”

About Mette-Marie Harild

Ms. Harild was most recently the regional VP of Medtronic’s largest sub-region in Europe, Middle East and Africa, leading Alpine, Benelux, Greece, Israel and Nordic countries. Before joining Medtronic, she held several leadership positions during her 16-year tenure with the Johnson & Johnson pharma company, Janssen, including sales director of Denmark and the Nordic sales director.

“I am thrilled to join the board of directors at Neurescue to help advance its next-generation balloon catheter technology in development, which has the potential to save the lives of the millions of people worldwide suffering from cardiac arrest each year,” said Mette-Marie Harild. “There has been little innovation in the treatment approach to cardiac arrest over the past several decades, and I am extremely proud to support the Neurescue team as they redefine the current standard of care for patients.”

Ms. Harild earned her executive MBA from the Aarhus School of Business in Denmark.

About Neurescue

Headquartered in Copenhagen, Denmark, Neurescue is a medical device company focused on developing innovative cardiovascular solutions to improve the outcomes of emergency patients. The company is dedicated to saving hearts and minds through the development of its NEURESCUE device, the world’s first computer-aided balloon catheter for aortic occlusion – a technique that supercharges blood flow to the brain and heart, aiming to increase resuscitation rates and buy additional treatment time for the patient. Neurescue holds more than 30 patents for their sensor-enabled, automated medical devices and is in the process of applying for an investigational device exemption for the cardiac arrest indication.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.